EMEA-003606-PIP01-24
Submitted by Anonymous (not verified) on 20 June 2025 - 14:05
EMEA-003606-PIP01-24
Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 20 June 2025 - 13:50
Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Date of authorisation: 22/11/2012, Revision: 9, Status: Authorised
EMEA-003605-PIP01-24
Submitted by Anonymous (not verified) on 20 June 2025 - 13:42
EMEA-003605-PIP01-24
EMEA-003600-PIP01-24
Submitted by Anonymous (not verified) on 20 June 2025 - 13:40
EMEA-003600-PIP01-24
Human medicines European public assessment report (EPAR): Axura, memantine, Date of authorisation: 17/05/2002, Revision: 29, Status: Authorised
Submitted by Anonymous (not verified) on 20 June 2025 - 13:30
Human medicines European public assessment report (EPAR): Axura, memantine, Date of authorisation: 17/05/2002, Revision: 29, Status: Authorised
Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 December 2025, 09:00 (CET) to 10 December 2025, 13:00 (CET)
Submitted by Anonymous (not verified) on 20 June 2025 - 12:53
Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 December 2025, 09:00 (CET) to 10 December 2025, 13:00 (CET)
Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - October 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 1 October 2025, 14:00 (CEST) to 3 October 2025, 18:00 (CEST)
Submitted by Anonymous (not verified) on 20 June 2025 - 12:52
Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - October 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 1 October 2025, 14:00 (CEST) to 3 October 2025, 18:00 (CEST)
Human medicines European public assessment report (EPAR): Colobreathe, colistimethate sodium, Date of authorisation: 13/02/2012, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 20 June 2025 - 12:29
Human medicines European public assessment report (EPAR): Colobreathe, colistimethate sodium, Date of authorisation: 13/02/2012, Revision: 19, Status: Authorised
Summary of opinion: Cabometyx, 19/06/2025 Positive
Submitted by Anonymous (not verified) on 20 June 2025 - 11:18
Summary of opinion: Cabometyx, 19/06/2025 Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025
Submitted by Anonymous (not verified) on 20 June 2025 - 11:00
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025